Perspectives on use of bevacizumab in patients with neuroendocrine tumors. Case report
Автор: Galina S. emelyanova, Nadezhda F. orel, Vera A. gorbunova, Alina A. kolomeitseva, Anna A. kuznetsova, Andrey E. kuzminov, Alexandr A. fedenko
Журнал: Сибирский онкологический журнал @siboncoj
Рубрика: Случай из клинической практики
Статья в выпуске: 6 т.16, 2017 года.
Бесплатный доступ
Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options for these patients. Approaches to the 2nd and subsequent lines of treatment have not been developed to date. VEGFR blocker bevacizumab is actively studied in well differentiated NET. For well differentiated NET, it has been shown that an increase in VEGF expression is associated with metastasis and decrease in progression-free survival.
Neuroendocrine tumors, bevacizumab
Короткий адрес: https://sciup.org/140254001
IDR: 140254001 | DOI: 10.21294/1814-4861-2017-16-6-100-104
